Literature DB >> 17874027

Sequential hydrodistension and intravesical instillation of hyaluronic acid under general anaesthesia for treatment of refractory interstitial cystitis: a pilot study.

Imran Ahmad1, Nalagatla Sarath Krishna, Robert N Meddings.   

Abstract

Pilot study looking at the combination of general anaesthetic hydrodistension and intravesical hyaluronic acid for treatment of refractory interstitial cystitis. Twenty-three treatment refractory patients were recruited with an average age 53.4 years. All underwent general anaesthetic cystoscopy, hydrodistension and instillation of hyaluronic acid (40 mg/50 ml). The bladder was then subsequently drained with the patient awake. Two initial treatments were carried out a month apart and duration between treatments increased depending upon symptom response. In the responders, the average number of treatments was 6.6 (median 4.5), duration between treatments was 3.1 months (median 2.6) and follow-up 15.8 months (median 16). Seventeen patients (74%) responded with immediate improvement in symptoms. In all responders, healing of ulceration and resolution of inflammation occurred. Average anaesthetic bladder capacity increased in the responder group from an average of 492 ml (median 500 ml) to an average of 776 ml (median 700 ml). Our pilot data suggests sequential hydrodistension and hyaluronic acid treatment under general anaesthesia may be considered for resistant cases of interstitial cystitis, especially those that cannot tolerate the instillation procedure under local anaesthesia. Further prospective trials are required.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17874027     DOI: 10.1007/s00192-007-0443-4

Source DB:  PubMed          Journal:  Int Urogynecol J Pelvic Floor Dysfunct


  11 in total

1.  Structure of hyaluronic acid in synovial fluid and its influence on the movement of solutes.

Authors:  N M Hadler; M A Napier
Journal:  Semin Arthritis Rheum       Date:  1977-11       Impact factor: 5.532

2.  The interstitial cystitis symptom index and problem index.

Authors:  M P O'Leary; G R Sant; F J Fowler; K E Whitmore; J Spolarich-Kroll
Journal:  Urology       Date:  1997-05       Impact factor: 2.649

3.  Uronate peaks and urinary hyaluronic acid levels correlate with interstitial cystitis severity.

Authors:  Vinata B Lokeshwar; Marie G Selzer; Darius J Unwala; Veronica Estrella; Maria-Fernanda Lorenzo Gomez; Roozbeh Golshani; Robert R Kester; David J Klumpp; Angelo E Gousse
Journal:  J Urol       Date:  2006-09       Impact factor: 7.450

4.  Antioxidant activity of synovial fluid, hyaluronic acid, and two subcomponents of hyaluronic acid. Synovial fluid scavenging effect is enhanced in rheumatoid arthritis patients.

Authors:  H Sato; T Takahashi; H Ide; T Fukushima; M Tabata; F Sekine; K Kobayashi; M Negishi; Y Niwa
Journal:  Arthritis Rheum       Date:  1988-01

Review 5.  The etiology of interstitial cystitis.

Authors:  T L Ratliff; C G Klutke; E M McDougall
Journal:  Urol Clin North Am       Date:  1994-02       Impact factor: 2.241

6.  Hyaluronate inhibition of cell proliferation.

Authors:  R L Goldberg; B P Toole
Journal:  Arthritis Rheum       Date:  1987-07

7.  Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis.

Authors:  A Morales; L Emerson; J C Nickel; M Lundie
Journal:  J Urol       Date:  1996-07       Impact factor: 7.450

8.  Clinical features and spectrum of light microscopic changes in interstitial cystitis.

Authors:  S L Johansson; M Fall
Journal:  J Urol       Date:  1990-06       Impact factor: 7.450

9.  Healing of hyaluronic acid-enriched wounds: histological observations.

Authors:  G Abatangelo; M Martelli; P Vecchia
Journal:  J Surg Res       Date:  1983-11       Impact factor: 2.192

Review 10.  The therapeutic role of sulfated polysaccharides in the urinary bladder.

Authors:  C L Parsons
Journal:  Urol Clin North Am       Date:  1994-02       Impact factor: 2.241

View more
  7 in total

1.  The role of sodium hyaluronate and sodium chondroitin sulphate in the management of bladder disease.

Authors:  Rocco Damiano; Antonio Cicione
Journal:  Ther Adv Urol       Date:  2011-10

2.  Combined intravesical sodium hyaluronate/chondroitin sulfate therapy for interstitial cystitis/bladder pain syndrome: a prospective study.

Authors:  Claudio Giberti; Fabrizio Gallo; Pierluigi Cortese; Maurizio Schenone
Journal:  Ther Adv Urol       Date:  2013-08

3.  Reduction of intercellular adhesion molecule 1 may play a role in anti-inflammatory effect of hyaluronic acid in a rat model of severe non-bacterial cystitis.

Authors:  Yuan Shao; Guo-liang Lu; Zhou-Jun Shen; Hong-chao He
Journal:  World J Urol       Date:  2012-02-23       Impact factor: 4.226

4.  A combined intravesical therapy with hyaluronic acid and chondroitin for refractory painful bladder syndrome/interstitial cystitis.

Authors:  M Cervigni; F Natale; L Nasta; A Padoa; R Lo Voi; D Porru
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-03-13

Review 5.  Intravesical treatments of bladder pain syndrome/interstitial cystitis.

Authors:  Jochen Neuhaus; Thilo Schwalenberg
Journal:  Nat Rev Urol       Date:  2012-11-27       Impact factor: 14.432

6.  A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis.

Authors:  Gionata Fiorino; Giacomo Carlo Sturniolo; Fabrizio Bossa; Andrea Cassinotti; Antonio di Sabatino; Paolo Giuffrida; Silvio Danese
Journal:  Cells       Date:  2019-05-30       Impact factor: 6.600

7.  A Novel Intravesical Dextrose Injection Improves Lower Urinary Tract Symptoms on Interstitial Cystitis/Bladder Pain Syndrome.

Authors:  Chin-Li Chen; Chien-Chang Kao; Ming-Hsin Yang; Gang-Yi Fan; Juin-Hong Cherng; Chih-Wei Tsao; Sheng-Tang Wu; Tai-Lung Cha; En Meng
Journal:  Front Pharmacol       Date:  2021-12-15       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.